Avammune Therapeutics

Avammune Therapeutics (formerly Straximm Therapeutics) is a drug discovery company focused on cancer immunotherapy. It develops non-nucleotidic small molecules inhibitors of Ectonucleotide Pyrophosphatase I (ENPP1), a negative regulator of the STING (stimulator of interferon genes) pathway, to combat cancer and infectious diseases.